| | 1.13 Mb.
 How To Read A SURF (MiLPDS)The Document Link below is rather large, well over 1 Meg. It has 79 pages, whereas each page explain the hyperlink from the first page. MilPDS_Code_Speedy_Reference The except below is what the front page looks like. MilPDS Code - Speedy Reference PERSONAL DATA - PRIVACY ACT OF 1974 (USC 552a) DISP-IND: AIRMAN ASSIGNMENT DATA 123456789 DOE, JANE L. SSG/ RJ 09 F7JK TYMX AREA 1 C/ST 48 FC A RS10 PAFSC 2S071 PSEI DOR 011001 *1ST ASGN* *2ND ASGN* *REQ ASGN* CAFSC 2S051 CSEI SRBWV- AAN- DAFSC 2S051 LANG AFQT- WCS- GPAS-- 2AFSC 2SEI GLOC/ AAR-- 3AFSC 3SEI DLA-0 RNLTD-- RAFSC- OJT--R PRP/SCI—DP 980206 DP-DT-- 1AAC-43 0203 1ALC- SC-S1 950124 CAFSC-- 2AAC- 2ALC- SDA- PCS/ASD— 3AAC- 3ALC- UIF- RSEL/WVR- VOL-RSGMT-APPL-NR- SCTY/AIC- CDA- TNG-SEI-- CONUS- MI / CS / TL- PB- OS/P- VL-ASG: ASSIGNMENT PREFERENCE / EQUAL 10-OCT-1997 SS-SP INT- S/TR-1 TR/ST-1 DS-00 040714 MIL-SP- REQ-DEROS-RS- ODSD-981017 DEROS-980206 STRD-981017 LST-DEROS-RS-YA DDC--960206 DDLDS-980206 DAS--980311 NOTIF-DT- ALC/AFSC- DOS--080103 TAFMS-951004 ETS--080103 CMPT-SEL- RAVL/DT- TOE-5 DOE-021004 RNL-AFSC- 2S051 PRJ-CRS S/R- MW PCS2 RE-1M RET/SEP- REQ/DOS- CE-4 DY-010220 NCOIC, STORAGE & ISSUE R/S-DT- HYT-A 1510 DOB-770628 CRS-DTD MS /DEP- M 01 CJR-N CIT-ST-1 TLCC-Y AAR/STAT-03 2PRJ-CRS ACC-ST- NCR- ASC- SRB-A ACF- 2CRS-DTD MAC/DT: 0 -- NOT IN ZONE 990903 EPRS-5B 5B 5B 5B 5B HISP DECL DECLINE TO RESPOND AQE--G6 A6 M4 E6 RACE DECLINED TO RESPOND EXPERIENCE INDICATOR BLOCK CNTL CODE Copyright © 2008 AFMENTOR. All rights reserved. View Terms and Conditions of Use . Revised: 10/21/09. Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Nature Medicine ( 2024 ) Cite this article Metrics details
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer to further these goals, testing promising new agents while optimizing individual outcomes. Here we tested datopotamab–deruxtecan (Dato-DXd) in the I-SPY2.2 trial for patients with high-risk stage 2/3 breast cancer. I-SPY2.2 uses a sequential multiple assignment randomization trial design that includes three sequential blocks of biologically targeted neoadjuvant treatment: the experimental agent(s) (block A), a taxane-based regimen tailored to the tumor subtype (block B) and doxorubicin–cyclophosphamide (block C). Patients are randomized into arms consisting of different investigational block A treatments. Algorithms based on magnetic resonance imaging and core biopsy guide treatment redirection after each block, including the option of early surgical resection in patients predicted to have a high likelihood of pathological complete response, the primary endpoint. There are two primary efficacy analyses: after block A and across all blocks for the six prespecified breast cancer subtypes (defined by clinical hormone receptor/human epidermal growth factor receptor 2 (HER2) status and/or the response-predictive subtypes). We report results of 103 patients treated with Dato-DXd. While Dato-DXd did not meet the prespecified threshold for success (graduation) after block A in any subtype, the treatment strategy across all blocks graduated in the hormone receptor-negative HER2 − Immune − DNA repair deficiency − subtype with an estimated pathological complete response rate of 41%. No new toxicities were observed, with stomatitis and ocular events occurring at low grades. Dato-DXd was particularly active in the hormone receptor-negative/HER2 − Immune − DNA repair deficiency − signature, warranting further investigation, and was safe in other subtypes in patients who followed the treatment strategy. ClinicalTrials.gov registration: NCT01042379 . This is a preview of subscription content, access via your institution Access optionsAccess Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 24,99 € / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 195,33 € per year only 16,28 € per issue Buy this article
Prices may be subject to local taxes which are calculated during checkout  Data availabilityDe-identified subject level data and/or clinical specimens are made available to members of the research community upon approval of the I-SPY Data Access and Publications Committee. Details of the application and review process are available at https://www.quantumleaphealth.org/for-investigators/clinicians-proposal-submissions/ . I-SPY aims to make complete patient-level clinical datasets available for public access within 6 months of publication, as the data is complex and requires extensive annotation to ensure its usability. Code availabilityThe statistical code used in this clinical trial is available to other investigators for approved research purposes. Investigators interested in accessing the code complete an application at https://www.quantumleaphealth.org/for-investigators/clinicians-proposal-submissions/ and include a brief description of the intended use. Access to the code will be granted upon approval of the request, subject to compliance with ethical guidelines and applicable institutional and regulatory requirements. Nanda, R. et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol. 6 , 676–684 (2020). Article PubMed Google Scholar Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382 , 810–821 (2020). Article CAS PubMed Google Scholar I-SPY2 Trial Consortium. Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer. JAMA Oncol. 6 , 1355–1362 (2020). Article Google Scholar Li, W. et al. Abstract P4-02-10: MRI models by response predictive subtype for predicting pathologic complete response. Cancer Res. 83 , P4-02-10 (2023). Google Scholar Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40 , 609–623.e6 (2022). Article CAS PubMed PubMed Central Google Scholar Onishi, N. et al. Abstract P3-03-01: functional tumor volume at 3 and 6 week MRI as an indicator of patients with inferior outcome after neoadjuvant chemotherapy. Cancer Res. 82 , P3-03-01 (2022). Onishi, N. et al. Prospective performance of an MRI algorithm for early re-direction of breast cancer neoadjuvant treatment. In Proc. 32nd Annual Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine (International Society for Magnetic Resonance in Medicine, 2024). Okajima, D. et al. Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol. Cancer Ther. 20 , 2329–2340 (2021). Article PubMed PubMed Central Google Scholar Sakach, E., Sacks, R. & Kalinsky, K. Trop-2 as a therapeutic target in breast cancer. Cancers 14 , 5936 (2022). Bardia, A. et al. Datopotamab deruxtecan in advanced or metastatic HR+/HER2− and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J. Clin. Oncol. 42 , 2281–2294 (2024). Gadaleta-Caldarola, G. et al. Safety evaluation of datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. Cancer Treat. Res. Commun. 37 , 100775 (2023). Dent, R. A. et al. TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 19 , 2349–2359 (2023). Bardia, A. et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther. Adv. Med. Oncol. 16 , 17588359241248336 (2024). Bardia, A. et al. TROPION-Breast01: datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2− breast cancer. Futur. Oncol. 20 , 423–436 (2024). Article CAS Google Scholar Rugo, H. S. et al. Adaptive randomization of veliparib–carboplatin treatment in breast cancer. N. Engl. J. Med. 375 , 23–34 (2016). Shatsky, R. A. et al. Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat. Med. https://doi.org/10.1038/s41591-024-03267-1 (2024). Lavori, P. W. & Dawson, R. Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clin. Trials 11 , 393–399 (2014). Li, W. et al. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. NPJ Breast Cancer 6 , 63 (2020). Symmans, W. F. et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25 , 4414–4422 (2007). Yau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 23 , 149–160 (2022). Common terminology criteria for adverse events (CTCAE) protocol development. CTEP National Cancer Institute https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (2021). Basch, E. et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J. Natl Cancer Inst. 106 , dju244 (2014). Jacob, S. et al. Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2. J. Clin. Oncol. 41 , 611 (2023). Pearman, T. P., Beaumont, J. L., Mroczek, D., O’Connor, M. & Cella, D. Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy. Cancer 124 , 991–997 (2018). Oken, M. M. et al. Toxicity and response criteria of the eastern-cooperative-oncology-group. Am. J. Clin. Oncol. 5 , 649–655 (1982). Cardoso, F. et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 375 , 717–729 (2016). Beltran, P. J. et al. Ganitumab (AMG 479) inhibits IGF-II–dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin. Cancer Res. 20 , 2947–2958 (2014). Pusztai, L. et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell 39 , 989–998.e5 (2021). Piccart, M. et al. 70-Gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22 , 476–488 (2021). Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9 , e002435 (2021). Haanen, J. et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33 , 1217–1238 (2022). Download references AcknowledgementsResearch reported in this paper was supported by the NCI of the National Institutes of Health (NIH) under award numbers P01CA210961 and U01CA225427 (L.J.E., N.H.). We acknowledge the generous support of the study sponsors and operations management, Quantum Leap Healthcare Collaborative (QLHC, 2013 to present) and the Foundation for the NIH (2010 to 2012; to L.J.E.). We sincerely appreciate the ongoing support for the I-SPY2.2 Trial from the Safeway Foundation, the William K. Bowes, Jr. Foundation, Give Breast Cancer the Boot and QLHC (all to L.J.E.) and the Breast Cancer Research Foundation (to L.J.E. and L.J.v.V.). We thank all the patients who volunteered to participate in I-SPY2. AstraZeneca provided funds and study drugs (datopotamab–deruxtecan and durvalumab). With the exception of QLHC, the funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank D. Wolf and J. Gibbs and the I-SPY patient advocates for all their important contributions to this work. Author informationThese authors contributed equally: Katia Khoury, Jane L. Meisel. Authors and AffiliationsUniversity of Alabama at Birmingham, Birmingham, AL, USA Katia Khoury & Erica Stringer-Reasor Emory University, Atlanta, GA, USA Jane L. Meisel & Kevin M. Kalinsky University of California San Francisco, San Francisco, CA, USA Christina Yau, Hope S. Rugo, A. Jo Chien, Ronald Balassanian, Cheryl Ewing, Wen Li, Natsuko Onishi, Adam L. Asare, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Elissa Price, Carolyn Beedle, Laura J. van ‘t Veer, Nola M. Hylton & Laura J. Esserman University of Chicago, Chicago, IL, USA North Carolina State University, Raleigh, NC, USA Marie Davidian & Butch Tsiatis University of California San Diego, San Diego, CA, USA Anne M. Wallace, Kay Yeung & Rebecca A. Shatsky University of California Davis, Davis, CA, USA Mili Arora & Candice Sauder Yale University, New Haven, CT, USA Mariya Rozenblit, Tara Sanft & Lajos Pusztai Columbia University, New York, NY, USA Dawn L. Hershman & Meghna S. Trivedi Oregon Health Sciences University, Portland, OR, USA Alexandra Zimmer & Ashton Outhaythip University of Pennsylvania, Philadelphia, PA, USA Amy S. Clark & Angela DeMichele University of Minnesota, Minneapolis, MN, USA Heather Beckwith & Douglas Yee University of Colorado Denver, Denver, CO, USA Anthony D. Elias The Mayo Clinic, Rochester, MN, USA Judy C. Boughey HOAG Family Cancer Institute, Newport Beach, CA, USA Chaitali Nangia Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA Christos Vaklavas Cooperman Barnabas Medical Center, New Brunswick, NJ, USA Coral Omene Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA Kathy S. Albain Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA Claudine Isaacs City of Hope Orange County Lennar Foundation Cancer Center, Orange County, CA, USA Jennifer Tseng University of Southern California, Los Angeles, CA, USA Evanthia T. Roussos Torres Sparrow Health System, Lansing, MI, USA Brittani Thomas Wake Forest University, Winston–Salem, NC, USA Alexandra Thomas & Brian Moore Sanford Health, Sioux Falls, SD, USA Amy Sanford Quantum Leap Healthcare Collaborative, San Francisco, CA, USA Adam L. Asare, Philip Beineke & Peter Norwood University of Texas MD Anderson Cancer Center, Houston, TX, USA W. Fraser Symmans & Paula Pohlmann The Gemini Group, Ann Arbor, MI, USA Jane Perlmutter You can also search for this author in PubMed Google Scholar ContributionsArm chaperones: J.L.M. and K.K. Leadership: C.Y., H.S.R., R.N., B.M., J.P., P.P., R.A.S., A.D., D.Y., L.J.v.V., N.M.H. and L.J.E. Study design: C.Y., M.D., B. Tsiatis, A.D., D.Y., L.J.v.V., N.M.H. and L.J.E. Formal analysis: C.Y. and P.N. Enrolled patients: J.L.M., K.K., H.S.R., R.N., A.J.C., A.M.W., M.A., M.R., D.L.H., A.Z., A.S.C., H.B., A.D.E., E.S.-R., J.C.B., C.N., C.V., C.O., K.S.A., K.M.K., C.I., J.T., E.T.R.T., B.T., A.T., A.S., R.B., C.E., K.Y., C.S., T.S., L.P., M.S.T., A.O., R.A.S., A.D., D.Y. and L.J.E. Laboratory studies: L.B.-S., G.L.H. and L.J.v.V. Imaging/pathology: W.L., N.O., W.F.S. and N.M.H. Data management: A.L.A. and P.B. Administration: G.L.H. and J.B.M. First draft: J.L.M., K.K., C.Y., P.N., J.B.M. and L.J.E. Edit and review: J.L.M., K.K., C.Y., H.S.R., R.N., M.D., B. Tsiatis, A.J.C., A.M.W., M.A., M.R., D.L.H., A.Z., A.S.C., H.B., A.D.E., E.S.-R., J.C.B., C.N., C.V., C.O., K.S.A., K.M.K., C.I., J.T., E.T.R.T., B. Thomas, A.T., A.S., R.B., C.E., K.Y., C.S., T.S., L.P., M.S.T., A.O., W.L., N.O., A.L.A., P.B., P.N., L.B.-S., G.L.H., J.B.M., B.M., W.F.S., E.P., C.B., J.P., P.P., R.A.S., A.D., D.Y., L.J.v.V., N.M.H. and L.J.E. Corresponding authorCorrespondence to Laura J. Esserman . Ethics declarationsCompeting interests. J.L.M. reports institutional research funding from AstraZeneca, Seagen, Sermonix and Olema and advisory and consulting roles with Pfizer, Seagen, Sermonix, Novartis, Stemline, AstraZeneca, Olema, GlaxoSmithKline and GE Healthcare. C.Y. reports institutional research grant from NCI/NIH; salary support and travel reimbursement from QLHC; a United States patent titled ‘Breast cancer response prediction subtypes’ (no. 18/174,491); and University of California Inventor Share. H.S.R. reports institutional research support from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann–La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly; Merck and Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambrx, Greenwich Pharma; and advisory and consulting roles with Chugai, Puma, Sanofi, Napo and Mylan. R.N. reports research funding from Arvinas, AstraZeneca, BMS, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma and Taiho and advisory roles with AstraZeneca, BeyondSpring, Daiichi Sankyo, Exact Sciences, Fujifilm, GE, Gilead, Guardant Health, Infinity, iTeos, Merck, Moderna, Novartis, OBI, OncoSec, Pfizer, Sanofi, Seagen and Stemline. M.D. reports research grants from NIH/NCI and NIH/NIA, and contracts from PCORI. A.J.C. reports institutional research funding from Merck, Amgen, Puma, Seagen, Pfizer and Olema and advisory roles with AstraZeneca and Genentech. A.Z. reports institutional research funding from Merck, honoraria for Medscape and participation on Pfizer Advisory Board. A.S.C. reports institutional research funding from Novartis and Lilly. A.D.E. reports support from Scorpion, Infinity and Deciphera. E.S.-R. reports grants from V Foundation, NIH, Susan G. Komen; institutional research funding from GSK, Seagen, Pfizer, Lilly; consulting and honoraria from Novartis, Merck, Seagen, AstraZeneca, Lilly; Cancer Awareness Network Board member and support from ASCO and NCCN. J.C.B. reports institutional research funding from Eli Lilly and SymBioSis, participation on the Data Safety Monitoring Committee of Cairn Surgical and honoraria from PER, PeerView, OncLive, EndoMag and UpToDate. C.V. reports institutional research funding from Pfizer, Seagen, H3 Biomedicine/Eisai, AstraZeneca, CytomX; research funding to previous institution from Genentech, Roche, Pfizer, Incyte, Pharmacyclics, Novartis, TRACON Pharmaceuticals, Innocrin Pharmaceuticals, Zymeworks and H3 Biomedicine; advisory and consulting roles with Guidepoint, Novartis, Seagen, Daiichi Sankyo, AstraZeneca and Cardinal Health; unpaid consulting with Genentech; and participation in non-CME activity with Gilead, AstraZeneca. C.O. reports consulting fees from AstraZeneca, Guardant Health and Jazz Pharmaceuticals. K.S.A. reports institutional research funding from AstraZeneca, Daiichi Sankyo, Seattle Genetics and QLHC; Independent Data and Safety Monitoring committee at Seattle Genetics. K.M.K. reports advisory and consultant roles for Eli Lilly, Pfizer, Novartis, AstraZeneca, Daiichi Sankyo, Puma, 4D Pharma, OncoSec, Immunomedics, Merck, Seagen, Mersana, Menarini Silicon Biosystems, Myovant, Takeda, Biotheranostics, Regor, Gilead, Prelude Therapeutics, RayzeBio, eFFECTOR Therapeutics and Cullinan Oncology; and reports institutional research funding from Genentech/Roche, Novartis, Eli Lilly, AstraZeneca, Daiichi Sankyo and Ascentage. C.I. reports institutional research funding from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, BMS, Genentech, Novartis and Regeneron; consultancy roles with AstraZeneca, Genentech, Gilead, ION, Merck, Medscape, MJH Holdings, Novartis, Pfizer, Puma and Seagen; and royalties from Wolters Kluwer (UptoDate) and McGraw Hill (Goodman and Gillman). J.T. serves as institutional principal investigator for clinical trial with Intuitive Surgical; editor lead for ABS, CGSO, SCORE, Breast Education Committee Track Leader, ASCO SESAP 19 and Breast Co-Chair, ACS. A.T. owns stock at Johnson and Johnsons, Gilead, Bristol Myers Squibb, reports participation on Pfizer Advisory Board: AstraZeneca and reports institutional research funding from Merck and Sanofi and royalties from UptoDate. R.B. reports a consultancy role at Genentech and stock ownership at Cerus Corp. K.Y. received research support unrelated to this work and paid to the institution from Pfizer, Gilead, Seagen, Dantari Pharmaceuticals, Treadwell Therapeutics, and Relay Therapeutics; support from American Cancer Society IRG grant no. IRG-19-230-48-IRG, UC San Diego Moores Cancer Center, Specialized Cancer Center support grant NIH/NCI P30CA023100, Curebound Discovery Award (2023, 2024). T.S. reports honoraria from Hologic. L.P. reports institutional research funding from Susan Komen Foundation, Breast Cancer Research Foundation, NCI, Pfizer, AstraZeneca, Menarini/Stemline, Bristol Myers Squibb, Merck and Co.; consulting fees from AstraZeneca, Merck, Novartis, Genentech, Natera, Personalis, Exact Sciences and Stemline/Menarini; patent titled ‘Method of measuring residual cancer and predicting patient survival’ (no. 7711494); and Data and Safety Monitoring Board member of the DYNASTY Breast02, OPTIMA and PARTNER trials. M.S.T. reports institutional research funding from Lilly, Gilead Sciences, Phoenix Molecular Designs, AstraZeneca, Regeneron, Merck and Novartis. A.L.A., P.B. and P.N. are employees of QLHC. G.L.H. reports institutional research grant from NIH (1R01CA255442). W.F.S. reports shares of IONIS Pharmaceuticals and Eiger Biopharmaceuticals, received consulting fees from AstraZeneca, is a cofounder with equity in Delphi Diagnostics and issued patents for (1) a method to calculate residual cancer burden and (2) genomic signature to measure sensitivity to endocrine therapy. J.P. reports honoraria from Methods in Clinical Research—faculty SCION workshop; support from ASCO and advocate scholarship; AACR—SSP program; VIVLI, U Wisc SPORE—EAB, QuantumLEAD—COVID DSMB, PCORI—reviewer and I-SPY advocate lead. P.P. reports institutional research funding from Genentech/Roche, Fabre-Kramer, Advanced Cancer Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, Cascadian Therapeutics, Bolt, Byondis, Seagen, Orum Therapeutics and Carisma Therapeutics; consulting fees from Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, Puma Biotechnology, Sirtex, CARIS Life sciences, Juniper, Bolt Biotherapeutics and AbbVie; honoraria from DAVA Oncology, OncLive/MJH Life Sciences, Frontiers—publisher, SABCS and ASCO; Speakers’ Bureau: Genentech/Roche (past); United States patent no. 8486413, United States patent no. 8501417, United States patent no. 9023362, United States patent no. 9745377; uncompensated roles with Pfizer, Seagen and Jazz. R.A.S. reports institutional research funding from OBI Pharma, QLHC, AstraZeneca and Gilead, serves on AstraZeneca and Stemline Advisory Boards and Gilead Speaker’s Bureau and reports consultancy role with QLHC. A.D. reports institutional research funding from Novartis, Pfizer, Genentech and NeoGenomics; Program Chair, Scientific Advisory Committee, ASCO. D.Y. reports research funding from NIH/NCI P30 CA 077598, P01 CA234228-01 and R01CA251600, consulting fees from Martell Diagnostics, and honoraria and travel for speaking at the ‘International Breast Cancer Conference.’ L.J.v.V. is a founding advisor and shareholder of Exai Bio and is a part-time employee and owns stock in Agendia. N.M.H. reports institutional research funding from NIH. L.J.E. reports funding from Merck and Co., participation on an advisory board for Blue Cross Blue Shield and personal fees from UpToDate and is an unpaid board member of QLHC. The other authors declare no competing interests. Peer reviewPeer review information. Nature Medicine thanks Barbara Pistilli and Sze-Huey Tan for their contribution to the peer review of this work. Primary Handling Editor: Ulrike Harjes, in collaboration with the Nature Medicine team. Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary informationSupplementary information. Supplementary figures and tables. Reporting SummaryRights and permissions. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Reprints and permissions About this articleCite this article. Khoury, K., Meisel, J.L., Yau, C. et al. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-03266-2 Download citation Received : 07 August 2024 Accepted : 23 August 2024 Published : 14 September 2024 DOI : https://doi.org/10.1038/s41591-024-03266-2 Share this articleAnyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative Quick links
Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.  |
IMAGES
VIDEO
COMMENTS
by order of the secretary of the air force department of the air force instruction 36-2110 9 august 2024 personnel total force assignments compliance with this publication is mandatory
The Assignment Management System (AMS) is a web application that houses multiple applications in support of officer assignments, enlisted assignments, commander responsibilities, and individual Air Force members. Users have access to a portion of their own personnel data and the ability to use manning tools, volunteer for available assignments, and review career field information using AMS.
I am a prior MAJCOM Functional Manager and a lot folks didn't understand Assignment Availability Codes/Assignment Limitation Codes. Also, not understanding priority levels of assignments (when discussing overseas returnees-mandatory movers-ordinary CONUS). ... Study finds 77% of Air Force unfit for civilian service duffelblog.
dafman36-2100 7 april 2021 5 attachment 1—glossary of references and supporting information 150 attachment 2—officer and enlisted adscs and health professions officer adscs 170 attachment 3—service commitments (ang only) 186 attachment 4—previous and current active duty service commitment reason codes with clear text titles 192
Secretary of the AF's publication improvements, deletes Deployment Availability Code table, updates Electronic Deployment Readiness guidance, adds "deployed teams" guidance, and revises compliance item tiering. Incorporates AFI 10-403 Air Force Guidance Memorandum 2019-01. ... assignment of forces. 1.4.2. Designates the Joint Staff as the ...
updates to Assignment Availability Codes and Assignment Limitation Codes reducing the use of acronyms, limiting the scope of this publication to the Department of the Air Force guidance, and lowering compliance tiers where possible. A margin bar (|) indicates newly revised material.
Assignment Availability Code (AAC) "CC" with an indefinite expiration date updated in MilPDS. (T-2). (Note: Airmen with an approved CCCA/CCCD the expiration is set to 12-months from approval. Once the 12 months have passed, the expiration date will again be set to indefinite.) (T-2).
Study with Quizlet and memorize flashcards containing terms like Operation Bootstrap, Article 15, Control Roster and more.
1.3.1.2. For any other duty or mobility restrictions assignment availability codes (AACs) 31, 37, or 81, the maximum allowable duration of the AF Form 469 is 365 days. 1.3.1.3. Fitness restrictions will be up to 365 days, unless the condition has been determined to be permanent, for which indefinite profiles can be created. (See Chapter 3
Rejects the assignment to the SRI (See note 2). 81 - 85 Included in AIMS. Rejects the assignment to DPAAS2 (See note 1). 86 - 88 Excluded in AIMS. Rejects the assignment to DPAAS2 (See note 2). 89 - 95 Included in AIMS. Allows the assignment to process with an action notice to DPAAS2 (See note 1).
They're likely talking about Assignment Availability Codes (Table 2.1, document pg. 110). To find out what code you may have, check your SURF on AMS by hovering over "Personnel Information" and clicking "My Career Brief". The "Assignment Info" page on the drop-down will show if you have an AAC or ALC (Assignment Limitation Code).
The except below is what the front page looks like. MilPDS Code - Speedy Reference. PERSONAL DATA - PRIVACY ACT OF 1974 (USC 552a) DISP-IND: AIRMAN ASSIGNMENT DATA. 123456789 DOE, JANE L. SSG/ RJ 09 F7JK TYMX AREA 1 C/ST 48 FC A RS10. PAFSC 2S071 PSEI DOR 011001 *1ST ASGN* *2ND ASGN* *REQ ASGN*.
deleted from the Airman's record. It will remain on file and if selected, the AFPC assignment team will process the appropriate waiver. 6.5. Assignment Availability Code (AAC) and Assignment Limitation Code (ALC): Airmen who have an AAC or ALC may apply depending on the AAC or ALC restrictions in DAFI 36-2110, paragraphs 6.11
4 DAFMAN 48-108 5 AUGUST 2021 5.3. MTF Action for return to duty with an Assignment Limitation Code..... 39 5.4. ARC service members are placed on ALC or DAV Code-42 by the appropriate
77 terms. vanessa_mercado36. Preview. Radio Codes (General) 7 terms. CodyWickert. Preview. Terms in this set (42) AAC. Assignment availability code, they are ineligible fir reassignment until their date of availability. ALC. Assignment limitation code, designed to restrict or limit selection of airmen for reassignment to or from certain duties ...
A personnel management tool, used to preclude or delay assignment selection of an Airman or group of Airmen when in the best interest of the AirForce. Stabilized Tour. An authorized period of time when Airmen must remain assigned to a particular unit or organization ton support a unique mission or function. Maximum Tour.
[email protected] 2. Class Assignments. 2.1. All selects must fill out the 'Active Duty Post-Selection Form' and send it to. [email protected]. 2.2. Air Force needs will dictate which AFSCs are assigned to a class first. 2.3. Please limit inquires on attaining class assignment dates.
(AF Forms 77) to JAX for all required legal internships (paragraphs 2.11.3 and 3.11.5.); clarifies that ... After receiving the application, HQ USAF/JAX enters an assignment availability code (code 24) to remain in effect until 1 June of the calendar year of application to indicate that the application for FLEP is pending. Within 10 calendar ...
DrunkARAMS. •. Deployable with Limitations. A dozen things could cause it. Really means member is deployable, but probably needs a waiver in many situations. May be there indefinitely or may fall off. Depends on the reason for it. 48-133 and the MSD. Reply.
availability and individual assignment preferences. (T-1). 3.2. Selection Requirements. RegAF Materiel Management Noncommissioned Officers holding Air Force Specialty Code 2S0XX and the appropriate enlisted grade can apply to participate in the career broadening program. Chain of Command approval is required. The
Code 50 and other r mandatory movers get assignments well before and leave just after the availability date. No reason to assume 36 is different. Soooooo I can't leave until after my expiration date is up? Currently in the shop we can't agree on what code 36 means for assignment availability. We know it means we're a mandatory mover.
%PDF-1.7 %âãÏÓ 81 0 obj >stream u ¢» áxíú¢dPÞwLj8öu\Ct q¤5ØDÒ¨š TÖ„SÖP!|æŽ! ‹ÎšQ²¡dv ¤ŒAϺkoÉ HzîÄœxî\ìü¬:Uûé š4²ûHst¿æÛtàm&Z´i¶´° K,£Ä…õ""Ò ¹€}³Ii0¦ÅV?\ ©ÂE¤ÄâÕ2 xPj4]„çåNíK cçâ (¢@Ö § ˆÙâìlŽ‡Ðo oÉ]ûdµÏQ@-=×—ßÁT ˆà s¼àÑk §—qh¡K Uäz õ×Å· ê#…ÃÔí罧« —ˆY øà «-VŽc ...
In the I-SPY2.2 trial, patients with high-risk stage 2/3 breast cancer received neoadjuvant datopotamab-deruxtecan, followed by sequential chemotherapy with or without targeted therapy, with the ...
If you're on a controlled tour with assignment availability code 50, you can't PCS until after your service commitment is up for the assignment you're on. There's no harm in applying for it. There's a chance you could be the most qualified candidate and your report date gets moved to match your code 50.